MBX Biosciences, Inc.
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -1.04% | 14.97% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -17.81% | 42.55% | |||
| Operating Income | 17.81% | -42.55% | |||
| Income Before Tax | 18.71% | -53.21% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 18.71% | -53.21% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 18.71% | -53.21% | |||
| EBIT | 17.81% | -42.55% | |||
| EBITDA | 17.80% | -42.58% | |||
| EPS Basic | 18.79% | -53.14% | |||
| Normalized Basic EPS | 18.80% | -28.92% | |||
| EPS Diluted | 18.79% | -53.14% | |||
| Normalized Diluted EPS | 18.80% | -28.92% | |||
| Average Basic Shares Outstanding | 0.10% | 0.06% | |||
| Average Diluted Shares Outstanding | 0.10% | 0.06% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||